Lead Investigator: Shuhua Yi, Peking Union Medical College
Title of Proposal Research: Clinical and molecular characteristics of Non-Hodgkin Lymphoma.
Vivli Data Request: 9822
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Non-Hodgkin lymphoma (NHL) is a diverse group of lymphoid cancers that affect the immune system. It is one of the most common types of cancer, with thousands of new cases diagnosed each year. Understanding both clinical and molecular characteristics of NHL is crucial for accurate diagnosis, prognosis (predicting the likely outcome), and choosing the best treatment options. Molecular characteristics include genetic changes identified through specialized tests, like next generation sequencing, performed on tumor tissue or blood samples. Clinical features such as age, gender, disease stage, and performance status (how well a patient can perform daily tasks) have been traditionally used to guide treatment decisions. However, recent advancements in research emphasize the value of combining clinical and molecular data to improve patient care.
This study aims to identify new clinical and molecular characteristics that influence lymphoma outcomes. We will analyze each variable individually to assess its association with progression-free survival (PFS)—the length of time during and after treatment before disease progression—and overall survival (OS)—the percentage of patients alive after a set period, such as five years.
By combining multiple types of data, this research has the potential to uncover previously unrecognized patterns and connections. Identifying and validating new factors could help clinicians better predict disease progression and tailor treatment strategies for individual patients. Ultimately, this may lead to improved patient outcomes and more cost-effective healthcare.
Requested Studies:
A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin’s Lymphoma
Data Contributor: Roche
Study ID: NCT00719472
Sponsor ID: U4391g
A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2, OR 3A
Data Contributor: Roche
Study ID: NCT01724021
Sponsor ID: MO28457
A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Data Contributor: Roche
Study ID: NCT01287741
Sponsor ID: BO21005
A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)
Data Contributor: Roche
Study ID: NCT01649856
Sponsor ID: MO28107
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Data Contributor: Roche
Study ID: NCT00281918
Sponsor ID: CDR0000454560
Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL
Data Contributor: Roche
Study ID: NCT00090051
Sponsor ID: 102-14
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions
Data Contributor: Roche
Study ID: NCT02242942
Sponsor ID: BO25323
An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.
Data Contributor: Roche
Study ID: NCT02053610
Sponsor ID: BO21004 (Stage 2)
A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab
Data Contributor: Roche
Study ID: NCT02005471
Sponsor ID: GO28667
An Open-label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Data Contributor: Roche
Study ID: NCT01414205
Sponsor ID: GAO4768g
An Adaptive, Comparative, Randomized, Parallel-group, Multi Center, Phase Ib Study of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With Chemotherapy (Fludarabine and Cyclophosphamide), in Patients With Previously Untreated CLL
Data Contributor: Roche
Study ID: NCT01292603
Sponsor ID: BO25341
A randomized, open-label, multi-center phase III trial comparing CVP + MabThera to standard CVP chemotherapy in patients with previously untreated follicular lymphoma.
Data Contributor: Roche
Study ID: M39021
Sponsor ID: M39021
A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV
Data Contributor: Roche
Study ID: NCT01200758
Sponsor ID: BO22334
An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin’s Lymphoma
Data Contributor: Roche
Study ID: NCT01059630
Sponsor ID: GAO4753g
A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin’s Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders
Data Contributor: Roche
Study ID: NCT01332968
Sponsor ID: BO21223
An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin’s Lymphoma
Data Contributor: Roche
Study ID: NCT00576758
Sponsor ID: BO21003
An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
Data Contributor: Takeda
Study ID: NCT01939899
Sponsor ID: C16017